バイオ医薬品において専門特化がこれまで以上に重要である理由

Our business has long been built for these demands, and now our brand reflects it

Author: Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Dept., Ajinomoto Co., Inc.

The growth of complex modalities is reshaping the development and manufacturing landscape, prompting many developers to reassess what they need from the right CDMO partner. Differentiation is increasingly defined by depth in a field, not just by broad capability. Areas such as HPAPI synthesis, ADC payload development, gene therapy manufacturing, and advanced linker chemistry now more than ever demand specialized expertise, dedicated infrastructure, and years of focused experience.

This is where Ajinomoto Bio-Pharma Services has built its entire business. Across our network of specialized CDMOs and enabling technologies, our teams maintain a laser focus on distinct areas of biopharma development and manufacturing. We do not aim to be everything to every developer. Across small molecules, oligonucleotides, peptides, gene therapy, proteins, and bioconjugates, our teams bring deep technical knowledge to the unique challenges of each modality.

That focus is strengthened by Ajinomoto Group’s remarkable scientific legacy of more than a century of innovation through “AminoScience.” This foundation has shaped a culture of scientific rigor, R&D excellence, and continuous innovation that extends across the organization. Within Aji Bio-Pharma, we apply that foundation to the unique needs of our clients, developing technologies and approaches that can help our clients unlock innovation and unleash the potential of their science.

Sustained focus within these areas gives our teams a clear view of where existing development and manufacturing processes have limitations and where new approaches can make a difference. That insight has contributed to technologies such as AJICAP™, our site-specific conjugation and linker technology that can help expand the therapeutic window and broaden bioconjugate design possibilities, as well as AJIPHASE™, our liquid-phase synthesis technology that helps overcome traditional scale limitations to make large-scale manufacturing of complex oligonucleotides and peptides more practical. Different technologies for very different modalities, but both examples reflect an approach grounded in deep technical focus and a broader commitment to scientific innovation in pursuit of supporting our clients and their patients.

Today, we are introducing a refreshed Aji Bio-Pharma brand that better reflects who we are. It brings these strengths together with the shared commitments that connect us across Aji Bio-Pharma, including quality, operational excellence, sustainability, and dependable partnership. Together, they shape how we support our clients and provide the reliability they depend on as they advance their programs. Our new brand brings that story into sharper focus and makes it easier for clients to understand and access the expertise, technologies, and capabilities across our organization.

The refreshed brand launches today, October 5, across Aji Bio-Pharma’s website and social media channels, and will appear at upcoming global conferences, with additional brand touchpoints transitioning to the new identity over the coming months.

It is a new, truer expression of our business, but our foundation remains the same, applying science and innovation to the challenges our biopharma clients face as they advance novel and complex medicines and, ultimately, help improve the health of humankind.